Clinical Context Diabetic erectile dysfunction (ED) affects 35-75% of men with diabetes and represents one of the most treatment-resistant forms…
Browsing: PICO
Clinical Context SGLT2 inhibitors like canagliflozin are cornerstone medications for type 2 diabetes, providing glycemic control alongside cardiovascular and renal…
Summary: In pregnant women enrolled in three blinded, prospective, randomized controlled trials, participation in structured prenatal exercise programs across three…
Clinical Context The diabetic heart has fundamentally altered metabolism. Insulin resistance impairs cardiac glucose uptake, forcing the myocardium to rely…
Clinical Context The GLP-1 receptor agonist (GLP-1 RA) class has expanded dramatically, with agents differentiated by dosing frequency (daily vs.…
Clinical Context GLP-1 receptor agonists produce substantial weight loss, but the mechanisms underlying this effect have been debated. Is weight…
Clinical Context Heart failure with preserved ejection fraction (HFpEF) represents one of the most challenging conditions in cardiovascular medicine. Unlike…
Clinical Context Type 2 diabetes ultimately results from beta-cell failure—the inability of pancreatic beta cells to produce sufficient insulin to…
Summary: In 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30 kg/m²) from the pooled STEP-HFpEF trials, semaglutide 2.4 mg…
Clinical Context Polycystic ovary syndrome (PCOS) affects 6-12% of reproductive-age women and extends far beyond reproductive concerns. It’s increasingly recognized…